Nishadh Sutaria is a Dermatology physician. OpenAlex indexes 56 publications with 1,241 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20255 payments
- Blueprint Medicines CorporationProgram year20252 payments
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
100%Calcium channel blocker57.7%Amlodipine Besylate100%Part D≥13 patientsAngiotensin receptor blocker (ARB)42.3%Losartan Potassium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Polygenic Risk Score for Predicting Racial and Genetic Susceptibility to Prurigo Nodularis
Journal of Investigative Dermatology
2023 - Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis
Journal of Investigative Dermatology
2022 - Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis
Journal of Dermatological Science
2022
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Modlin, MD
University of California, Los Angeles
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Joel Gelfand, MD
University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”